Immunocore (IMCR) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
UroGen Pharma (URGN) has outperformed Immunocore (IMCR) over the past year, gaining 113.4% versus a loss of 14.4%. Over five years, URGN leads with a +117.3% price change compared with -23.4% for IMCR. UroGen Pharma is the larger company by market cap ($1.82 billion vs $1.53 billion), about 1.2 times the size, while Immunocore is growing revenue faster (+29.0% vs +21.4%).
Immunocore converts more of its revenue into profit, with a net margin of -8.9% versus -139.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMCR | URGN |
|---|---|---|
| Share price | $29.62 | $37.27 |
| Market cap | $1.53B | $1.82B |
| 1-day change | +1.80% | +0.78% |
| YTD return | -16.19% | +57.90% |
| 1-year return | -14.42% | +113.39% |
| 5-year return | -23.45% | +117.27% |
| Forward P/E | — | 13.34 |
| EPS (TTM) | $-0.36 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $400.02M | $109.79M |
| Revenue growth (YoY) | +28.95% | +21.45% |
| Net income (latest FY) | $-35.51M | $-153.49M |
| Gross margin | 98.73% | 88.66% |
| Operating margin | -11.34% | -113.73% |
| Net margin | -8.88% | -139.81% |
| 52-week high | $40.72 | $50.81 |
| 52-week low | $27.56 | $15.86 |
| Distance from 52-week high | -27.26% | -26.65% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +111.82% | +60.99% |
| Average volume | 443.48K | 849.01K |
| Shares outstanding | 51.50M | 48.88M |
| Employees | 524 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed IMCR by 127.8 percentage points over the past year.
- Immunocore is more profitable, keeping -8.9 cents of every revenue dollar as net income versus -139.8 cents for UroGen Pharma.
- Immunocore grew revenue faster in its latest fiscal year (+28.95% vs +21.45%).
About Immunocore
IMCR stock →Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 524 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
IMCR vs URGN FAQ
Which is bigger, Immunocore or UroGen Pharma?
UroGen Pharma (URGN) is larger, with a market capitalization of $1.82B compared with $1.53B for Immunocore (IMCR).
Which stock has performed better over the past year, IMCR or URGN?
URGN returned +113.39% over the past 12 months, compared with -14.42% for IMCR (price return, excluding dividends). Past performance does not predict future results.
Are Immunocore and UroGen Pharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Immunocore and Biotechnology: Pharmaceutical Preparations for UroGen Pharma.